Hepatitis treatment coverage among infected population
Topic:
Hepatitis
Hepatitis treatment and care
Health service coverage
Rationale:
This indicator measures progress of treatment coverage among people living with chronic HBV and viraemic HCV infections, towards the 2030 hepatitis elimination goals.
Definition:
• Proportion of people with chronic hepatitis B initiated on treatment of those eligible
• Proportion of people with viraemic hepatitis C initiated on treatment
Disaggregation:
By country and WHO region
Method of measurement
HBV:
Numerator: Number of people with chronic hepatitis B ever initiated on treatment of those eligible. This may be sourced from specific programme or clinical patient monitoring tools (electronic or paper medical records)
Denominator: Estimated number of people living with chronic HBV. This can be derived from nationally representative biomarker survey or modelled estimates
HCV:
Numerator:Number of people with viraemic hepatitis C ever initiated on treatment. This may be sourced from specific programme or clinical patient monitoring tools (electronic or paper medical records)
Denominator: Estimated number of people living with viraemic HCV. This can be derived from nationally representative biomarker survey or modelled estimates.
For chronic HCV the denominator includes those with resolved infection (cured or naturally cleared) . all total HCV infections (all ages) since 2015. This intended to reflect the historical testing effort and treatment coverage. Those with re-infection are included but counted once.
This indicator is measured as part of routine surveillance from countries.
Where these data are unavailable, WHO leads a consultative process to produce country-calibrated modelled estimates of number of chronic hepatitis HBV and HCV infected persons ever initiated on treatment .
Method of estimation:
HBV model structure (PRoGReSs model): the HBV model uses a dynamic mathematical framework that estimates annual HBV prevalence and incidence by stage of liver disease, age and sex using disease progression and mortality (all-cause and liver-related) rates. The model integrates demographic profiles, vaccination coverage (including timely birth dose and three-dose infant
series), prevention measures such as hepatitis B immune globulin (HBIG) and maternal antiviral prophylaxis, HBV diagnosis and treatment schedules, and established HBV epidemiological parameters. Perinatal, early childhood and horizontal transmission are modelled using age-specific hepatitis B surface antigen (HBsAg) prevalence together with available prevention-coverage data. This allows the model to reflect both historical and current programme performance.
HCV model structure: the HCV model employs a Markov/semi-dynamic natural history framework that follows people with viraemic infection across stages of liver disease, by age and sex, over time using disease progression and mortality (all-cause and liver-related) rates. It incorporates inputs from demographic profiles, HCV diagnosis and treatment initiation schedules, and subsequent cure (sustained virological response, SVR)
Method of estimation of global and regional aggregates:
Estimates are also produced at global level and for WHO regions
Preferred data sources:
Surveillance systems
Facility registers and other program monitoring tools
Facility reporting system
Unit of Measure:
Percent
Expected frequency of data dissemination:
Every two years
Expected frequency of data collection:
Continuous at country level reported every two years to WHO
If you have any feedback, you are welcome to write it here.
If you need to access the old Global Health Observatory data, you can do it here. But before you leave, please provide us your feedback about our new data portal.
